Published: 28th Jul, 2022
Context
The World Health Organization has announced the launch of the world's first approved malaria vaccine across 3 African nations.
About
About the Vaccine
- The WHO recommendation is for RTS, S - or Mosquirix- a vaccine developed by British drug maker GlaxoSmithKline.
- Mosquirix's active component consists of proteins discovered on the outer layer of Plasmodium falciparum parasites (PFP).
- RTS, S aims to start the immune system in the early stages of malaria when PFP enters the bloodstream through a mosquito bite and infects liver cells.
- The RTS malaria vaccine, S/AS01, is used to protect children from falciparum malaria in locations with medium to high transmission.
- The most frequent kind of malaria in Africa is Falciparum.
- It is the very first and only vaccination that provides partial defense against young children.
- To lower the incidence and impact of malaria, children should be given the malaria vaccine in a four-dose schedule, beginning at age five months.
- The vaccine adds to the development of the malaria tool and can help get malaria control back on track.
- It also helps to keep the Hepatitis B virus from infecting the liver.
|
Malaria
|
Courses
Study
Notes
Home
Resources
More
